TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39037118

Group type: EXPERIMENTAL
Intervention: Simulated quick return
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard shift schedule)
Number of subjects: 0
Study: 39037163

Group type: EXPERIMENTAL
Intervention: Concave two-piece pouching system
Number of subjects: 53

Group type: COMPARATOR
Intervention: Comparator (two-piece pouching system with a flat skin barrier)
Number of subjects: 53
Study: 39037513

Group type: EXPERIMENTAL
Intervention: Decision Tree (DT) model for UIA instability
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Decision Tree (DT) model incorporating hypertension, aspect ratio, size ratio, bifurcation configuration, and irregular shape
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Multivariate Cox analysis
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Development cohort
Number of subjects: 1376
Study: 39037543

Group type: EXPERIMENTAL
Intervention: HR070803 (liposomal irinotecan) in combination with 5-fluorouracil and leucovorin, intravenous infusion from 60 to 80 mg/m²
Number of subjects: 0
Study: 39037709

Group type: EXPERIMENTAL
Intervention: Nitric Oxide (40 ppm) delivered via cardiopulmonary bypass circuit
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (no Nitric Oxide)
Number of subjects: 98
Study: 39037756

Group type: EXPERIMENTAL
Intervention: WeChat Quit Coach (intervention arm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-help print material (control arm)
Number of subjects: 60
Study: 39037762

Group type: EXPERIMENTAL
Intervention: Preoperative statin therapy
Number of subjects: 5592
Study: 39037768

Group type: EXPERIMENTAL
Intervention: Virtual parent coaching to deliver contingency management for emerging adults (CM-EA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: In-person peer recovery support services (PRSS) for emerging adults
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both virtual parent coaching and in-person PRSS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Parent CM-EA training adherence
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Payers and providers insights
Number of subjects: 48
Study: 39037799

Group type: EXPERIMENTAL
Intervention: Nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs, such as finerenone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin-aldosterone system inhibitors, statins/nonstatin alternatives, loop diuretics, anticoagulation agents, immunosuppressives, and lifestyle and dietary modifications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter-2 inhibitors
Number of subjects: 0
Study: 39037800

Group type: EXPERIMENTAL
Intervention: 1200 mg of risankizumab (induction trial)
Number of subjects: 975

Group type: COMPARATOR
Intervention: Placebo (induction trial)
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: 180 mg of risankizumab (maintenance trial)
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: 360 mg of risankizumab (maintenance trial)
Number of subjects: 975

Group type: COMPARATOR
Intervention: Placebo (maintenance trial)
Number of subjects: 975
Study: 39037811

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Case management plus financial incentives
Number of subjects: 192

Group type: COMPARATOR
Intervention: Financial incentives vs usual care
Number of subjects: 192

Group type: COMPARATOR
Intervention: Case management plus financial incentives vs usual care
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Case management plus financial incentives vs case management alone
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Case management plus financial incentives vs financial incentives alone
Number of subjects: 192
Study: 39037824

Group type: EXPERIMENTAL
Intervention: Difelikefalin; specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; specific treatment not available
Number of subjects: 0
Study: 39037964

Group type: EXPERIMENTAL
Intervention: Ibrutinib treatment
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Mathematical modeling
Number of subjects: 122
Study: 39037976

Group type: EXPERIMENTAL
Intervention: E-MATVR (Enhancing Men's Awareness of Testicular Diseases using Virtual Reality)
Number of subjects: 74

Group type: COMPARATOR
Intervention: E-MATE (Enhancing Men's Awareness of Testicular Diseases using Electric information)
Number of subjects: 74
Study: 39038011

Group type: EXPERIMENTAL
Intervention: Standardized sexual dysfunction (SD) screening intervention
Number of subjects: 86
Study: 39038096

Group type: EXPERIMENTAL
Intervention: Best medical treatment (BMT) plus endovascular treatment (EVT)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 340
Study: 39038251

Group type: EXPERIMENTAL
Intervention: Stockholm3
Number of subjects: 2129
Study: 39038265

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus carboplatin and paclitaxel
Number of subjects: 101
Study: 39038268

Group type: EXPERIMENTAL
Intervention: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) followed by high-dose melphalan (200 mg/m2)
Number of subjects: 90
Study: 39038282

Group type: EXPERIMENTAL
Intervention: Digital health coaching intervention, including asynchronous messages 1-2 times per week, unlimited access to the coach, and monthly videoconference or phone meetings over a 4-month period.
Number of subjects: 103
Study: 39038404

Group type: EXPERIMENTAL
Intervention: Desflurane-based volatile anesthesia
Number of subjects: 118

Group type: COMPARATOR
Intervention: Propofol-based total intravenous anesthesia
Number of subjects: 118
Study: 39038477

Group type: EXPERIMENTAL
Intervention: Heterologous HIV-1 vaccine regimen (Ad26.Mos4.HIV and clade C gp140)
Number of subjects: 2636

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: Heterologous HIV-1 vaccine regimen
Number of subjects: 2636
Study: 39038479

Group type: EXPERIMENTAL
Intervention: Luspatercept (1·0-1·75 mg/kg body weight, subcutaneously, once every 3 weeks)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Epoetin alfa (450-1050 IU/kg body weight, subcutaneously, once a week; max total dose 80,000 IU)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 363

Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 363
Study: 39038700

Group type: EXPERIMENTAL
Intervention: Exercise training (combined aerobic and resistance exercise)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Active control (flexibility and stretching)
Number of subjects: 50
Study: 39038701

Group type: EXPERIMENTAL
Intervention: First-, second-, or third-line systemic therapy for chronic GVHD
Number of subjects: 200
Study: 39038815

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at week 0, week 4, and every 12 weeks thereafter through week 52.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Number of subjects: 55
Study: 39038866

Group type: EXPERIMENTAL
Intervention: Paper-based exercises + video animations
Number of subjects: 132

Group type: COMPARATOR
Intervention: Paper-based exercises
Number of subjects: 132
Study: 39038917

Group type: EXPERIMENTAL
Intervention: IMA202 (autologous genetically modified cytotoxic CD8 T cells)
Number of subjects: 16
Study: 39038990

Group type: EXPERIMENTAL
Intervention: Topical menthol (1% menthol applied to hands and feet, two times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study: 39039005

Group type: EXPERIMENTAL
Intervention: General anesthesia with serratus plane block (group S)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: General anesthesia with thoracic epidural (group E)
Number of subjects: 80

Group type: COMPARATOR
Intervention: General anesthesia only (group G)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 39039086

Group type: EXPERIMENTAL
Intervention: C-JUN-overexpressing CAR-T cells
Number of subjects: 4
Study: 39039292

Group type: EXPERIMENTAL
Intervention: Primary endoscopic resection followed by esophagectomy (E group, n=36)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Esophagectomy alone (S group, n=298)
Number of subjects: 334
Study: 39039387

Group type: EXPERIMENTAL
Intervention: Spesolimab IV (450 mg, 900 mg, 1200 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Spesolimab SC (300 mg, 600 mg)
Number of subjects: 50
Study: 39039395

Group type: EXPERIMENTAL
Intervention: Sleep-Loss Scale
Number of subjects: 21
Study: 39039449

Group type: EXPERIMENTAL
Intervention: ABTL0812 (1300 mg tid) combined with carboplatin (AUC 5) and paclitaxel (175 mg/m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ABTL0812 (1300 mg tid)
Number of subjects: 12
Study: 39039458

Group type: EXPERIMENTAL
Intervention: Collaborative Behavioral Health Program (CBHP)
Number of subjects: 11
Study: 39039488

Group type: EXPERIMENTAL
Intervention: TIME case conferences structured based on cognitive behavioural therapy (CBT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TIME case conferences
Number of subjects: 6
Study: 39039509

Group type: EXPERIMENTAL
Intervention: Commercial carbohydrate-rich nutrition drink (Drink)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overnight peripheral parenteral nutrition (PPN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isotone Ringer-acetate (Control)
Number of subjects: 0
Study: 39039516

Group type: EXPERIMENTAL
Intervention: TCbIP regimen (inetetamab combined with pertuzumab, taxanes, and carboplatin)
Number of subjects: 44

Group type: COMPARATOR
Intervention: TCbHP regimen (trastuzumab combined with pertuzumab, taxanes, and carboplatin)
Number of subjects: 44
Study: 39039548

Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA)
Number of subjects: 5384

Group type: COMPARATOR
Intervention: Volatile anesthetics (GAS)
Number of subjects: 5384
Study: 39039560

Group type: EXPERIMENTAL
Intervention: E-WORTH intervention (n=172), a 5-session, culturally-tailored, group-based HIV prevention intervention including introduction to PrEP and access.
Number of subjects: 336

Group type: COMPARATOR
Intervention: HIV testing control group (n=180).
Number of subjects: 336
Study: 39039582

Group type: EXPERIMENTAL
Intervention: Real PL and real tES
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real PL and sham tES
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo PL and sham tES
Number of subjects: 0
Study: 39039609

Group type: EXPERIMENTAL
Intervention: Integrated management strategies including health worker training, adaptation of HIV EHR for HTN/CVD care, and use of treatment partners
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Integrated management strategies
Number of subjects: 290
Study: 39039666

Group type: EXPERIMENTAL
Intervention: Obinutuzumab-based immuno-chemotherapy and maintenance
Number of subjects: 299

Group type: COMPARATOR
Intervention: Pre-vaccination phase
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Post-vaccination phase
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 299
Study: 39039739

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) with OAC
Number of subjects: 180

Group type: COMPARATOR
Intervention: Medical management (MM) with OAC
Number of subjects: 180
Study: 39039833

Group type: EXPERIMENTAL
Intervention: TFP block (20 ml 0.25% bupivacaine for each side)
Number of subjects: 79

Group type: COMPARATOR
Intervention: TAP block (20 ml 0.25% bupivacaine for each side)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: TFP block
Number of subjects: 79

Group type: COMPARATOR
Intervention: TAP block
Number of subjects: 79
Study: 39039933

Group type: EXPERIMENTAL
Intervention: Functional chewing gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39040037

Group type: EXPERIMENTAL
Intervention: Integrative care (IC) model including ACS secondary prevention program and depression care (case screening, group counselling, individual problem-solving therapy)
Number of subjects: 4041

Group type: EXPERIMENTAL
Intervention: Integrative care (IC) model
Number of subjects: 4041

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 4041
Study: 39040184

Group type: EXPERIMENTAL
Intervention: IVIG (2 g/kg) alone
Number of subjects: 134

Group type: COMPARATOR
Intervention: IVIG (2 g/kg) with high-dose aspirin (80-100 mg/kg/day) until fever subsided for 48 hours, followed by daily aspirin (3-5 mg/kg) for six weeks
Number of subjects: 134
Study: 39040578

Group type: EXPERIMENTAL
Intervention: Brensocatib 10 mg
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg
Number of subjects: 1682

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1682
Study: 39040670

Group type: EXPERIMENTAL
Intervention: Celsior® solution
Number of subjects: 180

Group type: COMPARATOR
Intervention: St Thomas® solution
Number of subjects: 180
Study: 39040774

Group type: EXPERIMENTAL
Intervention: CT-STAR (cone beam computed tomography-guided stereotactic adaptive radiotherapy)
Number of subjects: 1
Study: 39040844

Group type: EXPERIMENTAL
Intervention: AK-EPQ (Actinic Keratosis Expert Panel Questionnaire)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AK-EPQ
Number of subjects: 0
Study: 39040882

Group type: EXPERIMENTAL
Intervention: ARCHES intervention
Number of subjects: 1492

Group type: COMPARATOR
Intervention: Control (standard counseling)
Number of subjects: 1492
Study: 39040887

Group type: EXPERIMENTAL
Intervention: CVnCoV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 0
Study: 39041200

Group type: EXPERIMENTAL
Intervention: Zanzalintinib + Atezolizumab
Number of subjects: 900

Group type: COMPARATOR
Intervention: Regorafenib
Number of subjects: 900
Study: 39041351

Group type: EXPERIMENTAL
Intervention: Purified granulocyte concentrates (GC)
Number of subjects: 0
Study: 39041411

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for 6 months with salvage radiotherapy (SRT)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) for 24 months with salvage radiotherapy (SRT)
Number of subjects: 534
Study: 39041887

Group type: EXPERIMENTAL
Intervention: Vaccine (Flublok; Sanofi Pasteur)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 447
Study: 39041933

Group type: EXPERIMENTAL
Intervention: Increased differential stroke volume (greater than 30 mL)
Number of subjects: 4058

Group type: COMPARATOR
Intervention: Balanced differential stroke volume (greater than or equal to -30 mL to ≤30 mL)
Number of subjects: 4058

Group type: EXPERIMENTAL
Intervention: Negative differential stroke volume (less than -30 mL)
Number of subjects: 4058
Study: 39042017

Group type: EXPERIMENTAL
Intervention: Vaginal hyaluronic acid (HLA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Vaginal estrogen
Number of subjects: 49
Study: 39042292

Group type: EXPERIMENTAL
Intervention: CT-P41 (60 mg subcutaneous)
Number of subjects: 479

Group type: COMPARATOR
Intervention: US-denosumab
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: CT-P41
Number of subjects: 479
Study: 39042310

Group type: EXPERIMENTAL
Intervention: Single-anastomosis duodeno-ileal bypass (SADI)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Biliopancreatic diversion with duodenal switch (BPD/DS)
Number of subjects: 56
Study: 39042407

Group type: EXPERIMENTAL
Intervention: ZY5301 300 mg/d
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ZY5301 600 mg/d
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 39042426

Group type: EXPERIMENTAL
Intervention: EHR-integrated digital platform (3-month intervention)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Standard-of-care assessment and addressing of social needs (3-month control)
Number of subjects: 295
Study: 39042439

Group type: EXPERIMENTAL
Intervention: MindCotine VR program
Number of subjects: 105
Study: 39042613

Group type: EXPERIMENTAL
Intervention: Vitamin D3 bolus (80,000 IU)
Number of subjects: 25
Study: 39042770

Group type: EXPERIMENTAL
Intervention: Bleselumab combined with tacrolimus and corticosteroids as maintenance immunosuppression
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard of care (SOC) comprising tacrolimus, mycophenolate mofetil, and corticosteroids
Number of subjects: 63
Study: 39042843

Group type: EXPERIMENTAL
Intervention: Symptom Care at Home (SCH)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 358
Study: 39042875

Group type: EXPERIMENTAL
Intervention: Algorithm designed to guide the deprescribing of drugs for OAB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 39042892

Group type: EXPERIMENTAL
Intervention: Quadrant 1 (high pre-HCT AUC ≥50 AU/day/mL, low post-HCT AUC <12 AU/day/L)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Quadrant 2 (low pre- and post-HCT AUC)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Quadrant 3 (low pre-HCT AUC, high post-HCT AUC)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Quadrant 4 (high pre- and post-HCT AUC)
Number of subjects: 163
Study: 39043009

Group type: EXPERIMENTAL
Intervention: Durvalumab 10 mg/kg plus Tremelimumab 3 mg/kg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg plus Tremelimumab 1 mg/kg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg plus Tremelimumab 1 mg/kg (dose expansion cohort)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Durvalumab 10 mg/kg plus Tremelimumab 1 mg/kg (dose expansion cohort)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All cohorts
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All dose-expansion cohorts
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 71
Study: 39043146

Group type: EXPERIMENTAL
Intervention: FYTF-919 (100 mL per day, oral)
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1504
Study: 39043201

Group type: EXPERIMENTAL
Intervention: Virtual Scale (VS) measurement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Visual measurement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Snare measurement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Visual and Snare measurements
Number of subjects: 120
Study: 39043348

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (ASA, 81 mg/day) during sleep restriction
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (ASA, 81 mg/day) during recovery sleep
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo during sleep restriction
Number of subjects: 46
Study: 39043397

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS)
Number of subjects: 12137

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 12137
Study: 39043416

Group type: EXPERIMENTAL
Intervention: Intraosseous access
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Intravenous access
Number of subjects: 1732
Study: 39043465

Group type: EXPERIMENTAL
Intervention: Patients with PD psychosis (PDP)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Patients with PD without psychosis (PDnP)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 676
Study: 39043513

Group type: EXPERIMENTAL
Intervention: StrataGraft treatment
Number of subjects: 52
Study: 39043586

Group type: EXPERIMENTAL
Intervention: Adolescents living with obesity (ALwO)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Caregivers of ALwO
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: ALwO discussing weight with HCPs
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: ALwO and caregivers seeking information
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Comfort level of ALwO and caregivers
Number of subjects: 416
Study: 39043588

Group type: EXPERIMENTAL
Intervention: Home-based peer support programme with standard care
Number of subjects: 442

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 442
Study: 39043593

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy plus health education (intervention group, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Health education (control group, n=20)
Number of subjects: 40
Study: 39043650

Group type: EXPERIMENTAL
Intervention: 20 min daily HVBR (fast breathing with long breath holds) for 3 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo HVBR (15 breaths/min with short breath holds) for 3 weeks
Number of subjects: 200
Study: 39043682

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PEX)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard of Care (Control)
Number of subjects: 22
Study: 39043871

Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) maintenance after ASCT
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: CD34+ hematopoietic stem cells (PBSC) harvesting and reinfusion
Number of subjects: 245
Study: 39043915

Group type: EXPERIMENTAL
Intervention: Milk supplementation (390 ml daily)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Dairy supplementation (meta-analysis)
Number of subjects: 315
Study: 39043982

Group type: EXPERIMENTAL
Intervention: Microsurgical resection with fMRI evaluation preoperatively and regular follow-up postoperatively.
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: LED performance for predicting unfavorable outcomes in compact BAVMs.
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: LED performance for predicting unfavorable outcomes in diffuse BAVMs.
Number of subjects: 346
Study: 39044019

Group type: EXPERIMENTAL
Intervention: Higher severity of common mental disorders (CMDs)
Number of subjects: 2486

Group type: EXPERIMENTAL
Intervention: Being unmarried (for women)
Number of subjects: 2486

Group type: EXPERIMENTAL
Intervention: No formal education (for men)
Number of subjects: 2486

Group type: EXPERIMENTAL
Intervention: Age ≥ 60 years
Number of subjects: 2486

Group type: EXPERIMENTAL
Intervention: Moderate and severe depression
Number of subjects: 2486

Group type: EXPERIMENTAL
Intervention: Moderate anxiety
Number of subjects: 2486